Efficacy and Safety of Systemic Tacrolimus in High-Risk Penetrating Keratoplasty After Graft Failure With Systemic Cyclosporine

Yamazoe, Kyoko; Yamazoe, Katsuya; Yamaguchi, Takefumi; Omoto, Masahiro; Shimazaki, Jun

doi:10.1097/ico.0000000000000258

Cited by 38 publications

(28 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Eight patients experienced rejection episodes while on tacrolimus, and this led to graft failure in 5 patients. In another study, Yamazoe et al 161 used systemic tacrolimus in patients with HR keratplasty who developed graft failure despite treatment with systemic CsA. They observed significantly fewer graft rejection episodes and longer graft survival with tacrolimus than with CsA.…”

Section: Management Of High-risk Corneal Transplantationmentioning

confidence: 99%

Management of high-risk corneal transplantation

Zazzo

Kheirkhah

Abud

et al. 2017

Survey of Ophthalmology

120

102

View full text Add to dashboard Cite

The cornea is the most commonly transplanted tissue in medicine. The main cause of corneal graft failure is allograft rejection. The incidence of graft rejection depends on the presence of high-risk characteristics, most notably corneal neovascularization. Although corneal graft has high success rates in the absence of these risk factors, high-risk keratoplasty is associated with low success rates due to a high incidence of immune-mediated graft rejection. To improve the survival of high-risk corneal transplantation, various preoperative, intraoperative, and postoperative measures can be considered. However, the key step in the management of these grafts is the long-term use of local and/or systemic immunosuppressive agents. Although a number of immunosuppressive agents have been employed for this purpose, the results vary significantly across different studies. This is partly due to the lack of an optimized method for their use as well as the lack of a precise stratification of the degree of risk in each individual patient. New targeted biologic treatments as well as tolerance-inducing methods show promising horizons in the management of high-risk corneal transplantation in near future.

show abstract

Section: Management Of High-risk Corneal Transplantationmentioning

confidence: 99%

Management of high-risk corneal transplantation

Zazzo

Kheirkhah

Abud

et al. 2017

Survey of Ophthalmology

120

102

View full text Add to dashboard Cite

show abstract

“…Systemic use of tacrolimus was also evaluated. It may be a safe and effective therapeutic modality in reducing rejection and prolonging graft survival in patients with high-risk keratoplasty [53, 62, 63]. …”

Section: Reviewmentioning

confidence: 99%

Topical tacrolimus in anterior segment inflammatory disorders

Shoughy

2017

Eye and Vis

View full text Add to dashboard Cite

Immune mediated inflammatory anterior segment diseases are variable and their management requires intense immunosuppression. Treatment with topical steroids is associated with serious ocular side effects. In order to overcome the potentially blinding complications of topical steroids, immunomodulatory drugs are being used more frequently. Tacrolimus is a calcineurin inhibitor that induces suppression of T lymphocytes activity and reduction of ocular inflammation. Tacrolimus was recently investigated for application in various anterior segment inflammatory disorders. In this review, we will discuss the therapeutic application of topical tacrolimus as a steroid-sparing agent in treating T cell mediated anterior segment inflammation.

show abstract

“…Yamazoe et al . reported that after tacrolimus systemic administration for treating high‐risk penetrating keratoplasty after graft failure with systemic cyclosporine in clinic, one of the patients suffered renal dysfunction and another one had muscle pain and fatigue.…”

Section: The Drug Treatment Of Cnvmentioning

confidence: 99%

Recent drug therapies for corneal neovascularization

Liu

Wang

et al. 2017

Chem Biol Drug Des

View full text Add to dashboard Cite

Corneal neovascularization (CNV) is a common pathological change in ocular surface diseases. It is not only the factor that affects vision but also the main cause for corneal graft failure. Based on the mechanism of CNV, many achievements have been developed to suppress the formation of CNV. There are certain novel drugs such as aflibercept, gold nanoparticles, and netrins which provide us with new clues to treat CNV. However, we still need to develop more effective therapeutic drugs. It is of great significance to develop new effective drugs to suppress the occurrence of CNV. In this paper, recent drug therapies for CNV are reviewed. The electronic database (PubMed) is searched for relative basic research and randomized clinical trials that are published recently.

show abstract

Efficacy and Safety of Systemic Tacrolimus in High-Risk Penetrating Keratoplasty After Graft Failure With Systemic Cyclosporine

Abstract: Treatment with systemic tacrolimus is possibly safe and effective in reducing graft rejection and prolonging graft survival in patients with high-risk PKP after graft failure with systemic CsA.

Cited by 38 publications

References 31 publications

Management of high-risk corneal transplantation

Management of high-risk corneal transplantation

Topical tacrolimus in anterior segment inflammatory disorders

Recent drug therapies for corneal neovascularization

Contact Info

Product

Resources

About